Antimetabolites in the treatment of arthritis: Current status of the use of antimetabolites

Nucleosides, Nucleotides and Nucleic Acids

Volumn 23, Issue 8-9, 2004, Pages 1083-1088

  Dijkmans, B A C ^a   Jansen, G ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Disease anti rheumatic modifying drugs; Leflunomide; Methotrexate; Rheumatoid arthritis

Indexed keywords

ANTIMETABOLITE; ANTIRHEUMATIC AGENT; CORTICOSTEROID; CYCLOSPORIN; ETANERCEPT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; SALAZOSULFAPYRIDINE; TERIFLUNOMIDE;

ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; AUTOIMMUNE DISEASE; CHRONIC INFLAMMATION; CONFERENCE PAPER; DISEASE ACTIVITY; DRUG EFFECT; DRUG EFFICACY; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; RHEUMATOID ARTHRITIS; T LYMPHOCYTE ACTIVATION;

ANTIMETABOLITES; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; ISOXAZOLES; METHOTREXATE; TIME FACTORS;

EID: 10344224567     PISSN: 15257770     EISSN: None     Source Type: Journal    
DOI: 10.1081/NCN-200027360     Document Type: Conference Paper

References (27)

1. Feldmann, M.; Brennan, F.M.; Maini, R.N. Rheumatoid arthritis. Cell 1996, 85, 307-310.
2. Smolen, J.S.; Steiner, G. Therapeutic strategies for rheumatoid arthritis. Nat. Rev., Drug Discov. 2003, 2, 473-488.
3. Elliott, M.J.; Maini, R.N.; Feldmann, M.; Kalden, J.R.; Antoni, C.; Smolen, J.S.; Leeb, B.; Breedveld, F.C.; Macfarlane, J.D.; Bijl, H. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994, 344, 1105-1110.
4. Furst, D.E.; Breedveld, F.C.; Kalden, J.R.; Smolen, J.S.; Antoni, C.E.; Bijlsma, J.W.; Burmester, G.R.; Cronstein, B.; Keystone, E.C.; Kavanaugh, A.; Klareskog, L. Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002). Ann. Rheum. Dis. 2002, 61 (Suppl. 2), ii2-ii7.
5. Lipsky, P.E.; van der Heijde, D.M.; St. Clair, E.W.; Furst, D.E.; Breedveld, F.C.; Kalden, J.R.; Smolen, J.S.; Weisman, M.; Emery, P.; Feldmann, M.; Harriman, G.R.; Maini, R.N. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N. Engl. J. Med. 2000, 343, 1594-1602.
6. Bathon, J.M.; Martin, R.W.; Fleischmann, R.M.; Tesser, J.R.; Schiff, M.H.; Keystone, E.C.; Genovese, M.C.; Wasko, M.C.; Moreland, L.W.; Weaver, A.L.; Markenson, J.; Finck, B.K. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N. Engl. J. Med. 2000, 343, 1586-1593.
7. Weinblatt, M.E.; Trentham, D.E.; Fraser, P.A.; Holdsworth, D.E.; Falchuk, K.R.; Weissman, B.N.; Coblyn, J.S. Long-term prospective trial of low-dose methotrexate in rheumatoid arthritis. Arthritis Rheum. 1988, 31, 167-175.
8. Cronstein, B.N. Molecular therapeutics. Methotrexate and its mechanism of action. Arthritis Rheum. 1996, 39, 1951-1960.
9. Genestier, L.; Paillot, R.; Quemeneur, L.; Izeradjene, K.; Revillard, J.P. Mechanisms of action of methotrexate. Immunopharmacology 2000, 47, 247-257.
10. Cutolo, M.; Sulli, A.; Pizzorni, C.; Seriolo, B.; Straub, R.H. Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis. Ann. Rheum. Dis. 2001, 60, 729-735.
11. Weinblatt, M.E.; Polisson, R.; Blotner, S.D.; Sosman, J.L.; Aliabadi, P.; Baker, N.; Weissman, B.N. The effects of drug therapy on radiographic progression of rheumatoid arthritis. Results of a 36-week randomized trial comparing methotrexate and auranofin. Arthritis Rheum. 1993, 36, 613-619.
12. Molenaar, E.T.; Voskuyl, A.E.; Dinant, H.J.; Bezemer, P.D.; Boers, M.; Dijkmans, B.A.C. Progression of radiographic damage in patients with rheumatoid arthritis in clinical remission. Arthritis Rheum. 2004, 50, 36-42.
13. van Ede, A.E.; Laan, R.F.; Rood, M.J.; Huizinga, T.W.; van de Laar, M.A.; van Denderen, C.J.; Westgeest, T.A.; Romme, T.C.; de Rooij, D.J.; Jacobs, M.J.; de Boo, T.M.; van der Wilt, G.J.; Severens, J.L.; Hartman, M.; Krabbe, P.F.; Dijkmans, B.A.; Breedveld, F.C.; van de Putte, L.B. Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2001, 44, 1515-1524.
14. Goekoop, Y.P.; Allaart, C.F.; Breedveld, F.C.; Dijkmans, B.A. Combination therapy in rheumatoid arthritis. Curr. Opin. Rheumatol. 2001, 13, 177-183.
15. Haagsma, C.J.; van Riel, P.L.; de Jong, A.J.; van de Putte, L.B. Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial. Br. J. Rheumatol. 1997, 36, 1082-1088.
16. Dougados, M.; Combe, B.; Cantagrel, A.; Goupille, P.; Olive, P.; Schattenkirchner, M.; Meusser, S.; Paimela, L.; Rau, R.; Zeidler, H.; Leirisalo-Repo, M.; Peldan, K. Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Ann. Rheum. Dis. 1999, 58, 220-225.
17. Boers, M.; Verhoeven, A.C.; Markusse, H.M.; van de Laar, M.A.; Westhovens, R.; van Denderen, J.C.; van Zeben, D.; Dijkmans, B.A.; Peeters, A.J.; Jacobs, P.; van den Brink, H.R.; Schouten, H.J.; van der Heijde, D.M.; Boonen, A.; van Der, L.S. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997, 350, 309-318.
18. Landewe, R.B.; Boers, M.; Verhoeven, A.C.; Westhovens, R.; van de Laar, M.A.; Markusse, H.M.; van Denderen, J.C.; Westedt, M.L.; Peeters, A.J.; Dijkmans, B.A.; Jacobs, P.; Boonen, A.; Der Heijde, D.M.; van Der, L.S. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum. 2002, 46, 347-356.
19. O'Dell, J.R.; Leff, R.; Paulsen, G.; Haire, C.; Mallek, J.; Eckhoff, P.J.; Fernandez, A.; Blakely, K.; Wees, S.; Stoner, J.; Hadley, S.; Felt, J.; Palmer, W.; Waytz, P.; Churchill, M.; Klassen, L.; Moore, G. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002, 46, 1164-1170.
20. Williamson, R.A.; Yea, C.M.; Robson, P.A.; Curnock, A.P.; Gadher, S.; Hambleton, A.B.; Woodward, K.; Bruneau, J.M.; Hambleton, P.; Spinella-Jaegle, S.; Morand, P.; Courtin, O.; Sautes, C.; Westwood, R.; Hercend, T.; Kuo, E.A.; Ruuth, E. Dihydroorotate dehydrogenase is a target for the biological effects of leflunomide. Transplant. Proc. 1996, 28, 3088-3091.
21. Fox, R.I. Mechanism of action of leflunomide in rheumatoid arthritis. J. Rheumatol., Suppl. 1998, 53, 20-26.
22. Breedveld, F.C.; Dayer, J.M. Leflunomide: mode of action in the treatment of rheumatoid arthritis. Ann. Rheum. Dis. 2000, 59, 841-849.
23. Williamson, R.A.; Yea, C.M.; Robson, P.A.; Curnock, A.P.; Gadher, S.; Hambleton, A.B.; Woodward, K.; Bruneau, J.M.; Hambleton, P.; Spinella-Jaegle, S.; Morand, P.; Courtin, O.; Sautes, C.; Westwood, R.; Hercend, T.; Kuo, E.A.; Ruuth, E. Dihydroorotate dehydrogenase is a target for the biological effects of leflunomide. Transplant. Proc. 1996, 28, 3088-3091.
24. Silva, H.T., Jr.; Morris, R.E. Leflunomide and malononitrilamides. Am. J. Med. Sci. 1997, 313, 289-301.
25. Mladenovic, V.; Domljan, Z.; Rozman, B.; Jajic, I.; Mihajlovic, D.; Dordevic, J.; Popovic, M.; Dimitrijevic, M.; Zivkovic, M.; Campion, G. Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Results of a randomized, placebo-controlled, phase II study. Arthritis Rheum. 1995, 38, 1595-1603.
26. Strand, V.; Cohen, S.; Schiff, M.; Weaver, A.; Fleischmann, R.; Cannon, G.; Fox, R.; Moreland, L.; Olsen, N.; Furst, D.; Caldwell, J.; Kaine, J.; Sharp, J.; Hurley, F.; Loew-Friedrich, I. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch. Intern. Med. 1999, 159, 2542-2550.
27. Smolen, J.S.; Kalden, J.R.; Scott, D.L.; Rozman, B.; Kvien, T.K.; Larsen, A.; Loew-Friedrich, I.; Oed, C.; Rosenburg, R. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet 1999, 353, 259-266.